5th Edition of International Heart Congress
June 24-26, 2027 | Hybrid Event
Ischemic Heart Diseases
Ischemic heart diseases often referred to as coronary artery disease, occur when blood flow to the heart is reduced due to narrowed or blocked coronary arteries. This restriction, usually caused by atherosclerosis, deprives the heart muscle of oxygen and nutrients, leading to symptoms like chest pain (angina), fatigue, and shortness of breath. Severe or prolonged ischemia can result in a heart attack, posing life-threatening risks. Managing ischemic heart diseases involves lifestyle changes, medications to improve blood flow, and medical interventions like stenting or bypass surgery. Early diagnosis and treatment play a vital role in preventing complications and improving long-term cardiac health. With ongoing advancements in cardiology, innovative therapies are offering patients new opportunities for recovery and improved quality of life.
John R Doty
Intermountain Medical Center, United States
Agustin Joison
Cordoba Catholic University, Argentina
Thomas J Webster
Brown University, United States
Uwe Peter Tigor
Auxilius Pharma, United States
Sergey Suchkov
N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Bijoy Krishna Banik
National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, IndiaSubmit your abstract Today
Title : Healing a broken heart: One nano beat at a time
Thomas J Webster, Brown University, United States
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Antidiabetic agents – From treating diabetes to providing positive cardiovascular outcome
Syed Raza, Awali Hospital, Bahrain